Imagen de portada del espectáculo Talking About Tumors with Ryann and Ryan - A medical oncology podcast

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

Podcast de Talking About Tumors

inglés

Tecnología y ciencia

Oferta limitada

2 meses por 1 €

Después 4,99 € / mesCancela cuando quieras.

  • 20 horas de audiolibros / mes
  • Podcasts exclusivos
  • Podcast gratuitos
Empezar

Acerca de Talking About Tumors with Ryann and Ryan - A medical oncology podcast

Designed for residents and fellows to provide an overview of the clinical practice and evidence behind management of each individual tumor site. Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, cancer

Todos los episodios

50 episodios

Portada del episodio 05_02 Neuroendocrine Tumors

05_02 Neuroendocrine Tumors

1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1–10 1.   Kunz PL  et al. Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013/ 2.  Strosberg JR et al. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6 3.  Strosberg J  et al. NEJM. 2017;376(2):125-135. doi:10.1056/NEJMOA1607427/ 4.  Caplin ME et al. NEJM. 2014;371(3):224-233. doi:10.1056/NEJMOA1316158/ 5.   Caplin ME et al. Endocrine. 2021;71(2):502-513. doi:10.1007/S12020-020-02475-6.  Neuroendocrine Tumor Guidelines, ESMO. Accessed May 1, 2025. https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-endocrine-and-neuroendocrine-cancers 7.   Pieterman CRC  , et al. J Neuroendocrinol. Published online January 1, 2024. doi:10.1111/JNE.13468 8.   NANETS. Accessed May 1, 2025. https://nanets.net/ 9.  Rinke A et al. Results of long-term survival. Neuroendocrinology. 2016;104(1):26-32. doi:10.1159/000443612, 10. Rinke A et al. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510,   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

3 de may de 2025 - 27 min
Portada del episodio 05_01 Hepatocellular carcinoma

05_01 Hepatocellular carcinoma

1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.           Finn RS, et al. Oncologist. 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183 2.           Pfister D et al. Nature 2021 592:7854. 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0 3.           Zhu AX  et al. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9 4.           Abou-Alfa GK, et al. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDOA2100070 5.           Kudo M, et al. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1 7.           Llovet JM, et al. NEJM. 2008;359(4):378-390. doi:10.1056/NEJMOA0708857 8.           Reig M, et al.. J Hepatol. 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018 9.           Cheng AL et al.  J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030 10.        Finn RS et al. NEJM. 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/ 11.        Rose S, et al. Lancet. 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

19 de dic de 2024 - 32 min
Portada del episodio 04_10 Testicular Cancer II

04_10 Testicular Cancer II

1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer.   1.          Pico JL et al. Ann Oncol. 2005;16(7):1152-1159. doi:10.1093/ANNONC/MDI228 2.          Adra N, et al. J Clin Oncol. 2017;35(10):1096-1102. doi:10.1200/JCO.2016.69.5395 3.          Nichols CR et al. J Clin Oncol. 1998;16(4):1287-1293. doi:10.1200/JCO.1998.16.4.1287 4.          de Wit R et al.. JCO. 1997;15(5):1837-1843. doi:10.1200/JCO.1997.15.5.1837 5.          Culine S, et al.  Ann Oncol. 2007;18(5):917-924. doi:10.1093/ANNONC/MDM062 6.          Lorch A, et al. Journal of Clinical Oncology. 2007;25(18_suppl):5086-5086. doi:10.1200/JCO.2007.25.18_SUPPL.5086 7.          Fung C, et al.. J Natl Compr Canc Netw. 2019;17(12):1557-1568. doi:10.6004/JNCCN.2019.7369   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

27 de oct de 2024 - 25 min
Portada del episodio 04_09 Testicular Cancer I

04_09 Testicular Cancer I

1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease   Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.          Hiester A et al. Eur J Cancer. 2021;155:64-72. doi:10.1016/J.EJCA.2021.06.022 2.          Calaway AC et al. Eur Urol. 2019;76(5):607-609. doi:10.1016/j.eururo.2019.05.031 3.          Oliver RTD et al. J Clin Oncol. 2011;29(8):957-962. doi:10.1200/JCO.2009.26.4655 4.          Oliver RTD et al. Lancet. 2005;366(9482):293-300. doi:10.1016/S0140-6736(05)66984-X 5.          Joffe JK et al. JCO. 2022;40(22):2468-2478. doi:10.1200/JCO.21.01199/ 6.          Bhatia S et al.. J NCCN. 2023;21(8):851-880. doi:10.6004/JNCCN.2023.0040 7.          Stephenson A et al. J Urol. 2019;202(2):272-281. doi:10.1097/JU.0000000000000318     Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

18 de sep de 2024 - 28 min
Portada del episodio 04_08 Metastatic Renal Cell Carcinoma

04_08 Metastatic Renal Cell Carcinoma

1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Flanigan RC et al.  J Urol.  2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae 2. Bex A et al. JAMA Oncology. 2019;5(2):164-170.  doi:10.1001/jamaoncol.2018.5545 3. Mejean A et al. NEJM.  2018;379:417-427. doi:10.1056/NEJMoa1803675 4. Motzer RJ et al.  NEJM.  2007;356:115-124. doi:10.1056/NEJMoa065044 5. Rini BI et al.  NEJM.  2019;380:1116-1127. doi:10.1056/NEJMoa1816714 6. Rini BI et al. JCO.  2023;41(17 Supp).  doi:10.1200/JCO.2023.41.17_suppl.LBA4501 7. Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023 8. Motzer RJ et al. NEJM. 2018;378:1277-1290.  doi:10.1056/NEJMoa1712126 9. Motzer R et al.  NEJM.  2021;384:1289-1300.  doi:10.1056/NEJMoa2035716 10. Albiges L et al.  Ann Oncol.  2023;34(2 Supp):S1329-S1330.  doi:10.1016/j.annonc.2023.10.090 11. Jonasch E.  ASCO Annual Meeting presented May 31, 2024 in Chicago, IL   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

2 de ago de 2024 - 24 min
Soy muy de podcasts. Mientras hago la cama, mientras recojo la casa, mientras trabajo… Y en Podimo encuentro podcast que me encantan. De emprendimiento, de salid, de humor… De lo que quiera! Estoy encantada 👍
Soy muy de podcasts. Mientras hago la cama, mientras recojo la casa, mientras trabajo… Y en Podimo encuentro podcast que me encantan. De emprendimiento, de salid, de humor… De lo que quiera! Estoy encantada 👍
MI TOC es feliz, que maravilla. Ordenador, limpio, sugerencias de categorías nuevas a explorar!!!
Me suscribi con los 14 días de prueba para escuchar el Podcast de Misterios Cotidianos, pero al final me quedo mas tiempo porque hacia tiempo que no me reía tanto. Tiene Podcast muy buenos y la aplicación funciona bien.
App ligera, eficiente, encuentras rápido tus podcast favoritos. Diseño sencillo y bonito. me gustó.
contenidos frescos e inteligentes
La App va francamente bien y el precio me parece muy justo para pagar a gente que nos da horas y horas de contenido. Espero poder seguir usándola asiduamente.

Elige tu suscripción

Más populares

Oferta limitada

Premium

20 horas de audiolibros

  • Podcasts exclusivos

  • Disfruta los podcast de Podimo sin anuncios

  • Cancela cuando quieras

2 meses por 1 €
Después 4,99 € / mes

Empezar

Premium Plus

100 horas de audiolibros

  • Podcasts exclusivos

  • Disfruta los podcast de Podimo sin anuncios

  • Cancela cuando quieras

Disfruta 30 días gratis
Después 9,99 € / mes

Prueba gratis

Sólo en Podimo

Audiolibros populares

Preguntas frecuentes

Más preguntas y respuestas
Empezar

2 meses por 1 €. Después 4,99 € / mes. Cancela cuando quieras.